Nanoparticles for protein drug delivery
View Patent ↗The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
1. A method of treating diabetes in a subject, comprising administering bioactive nanoparticles to said subject, wherein said bioactive nanoparticles consist of a positively charged chitosan, a negatively charged organic compound, and at least one anti-diabetic drug, wherein a shell portion of said nanoparticles is dominated by said positively charged chitosan, and wherein a core portion of said nanoparticles is formed by electrostatically complexing the positively charged chitosan and said negatively charged.
2. The method of claim 1 , wherein the chitosan is N-trimethyl chitosan, EDTA-chitosan, or chitosan derivatives.
3. The method of claim 1 , wherein said nanoparticles have a mean particle size between about 50 and 400 nanometers.
4. The method of claim 1 , wherein said nanoparticles are loaded in tablets or pills.
5. The method of claim 1 , wherein said nanoparticles are encapsulated in a capsule.
6. The method of claim 5 , wherein said capsule further comprises a second anti-diabetic drug which is different from said at least one anti-diabetic drug in said bioactive nanoparticles.
7. The method of claim 5 , wherein said capsule further comprises at least a solubilizer or a pharmacopocial excipient.
8. The method of claim 5 , wherein said capsule further comprises an absorption enhancer.
9. The method of claim 8 , wherein said absorption enhancer is selected from the group consisting of Ca 2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives.
10. The method of claim 1 , wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form.
11. The method of claim 1 , wherein said nanoparticles are mixed with trehalose and then freeze-dried, thereby said nanoparticles being in a powder form.
12. The method of claim 1 , wherein said nanoparticles further comprise magnesium sulfate or TPP.
13. The method of claim 1 , wherein said anti-diabetic drug is insulin or insulin analog.
14. The method of claim 1 , wherein said anti-diabetic drug is an insulin sensitizer.
15. The method of claim 1 , wherein said anti-diabetic drug is an insulin secretagogue.
16. The method of claim 1 , wherein said anti-diabetic drug is a GLP-1 analog.
17. The method of claim 1 , wherein said anti-diabetic drug is an inhibitor of dipeptidyl peptidase 4 (DIP-4 inhibitor).
18. The method of claim 1 , wherein said anti-diabetic drug is exenatide, liraglutide, albiglutide, or taspoglutide.
19. The method of claim 1 , wherein said anti-diabetic drug is selected from the group consisting of alpha-glucosidase inhibitors, amylin analog, sodium-glucose co-transporter type 2 (SGLT2) inhibitors, benfluorex, and tolrestat.